Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P0DOY2

UPID:
IGLC2_HUMAN

ALTERNATIVE NAMES:
Ig lambda chain C region Kern; Ig lambda chain C region NIG-64; Ig lambda chain C region SH; Ig lambda chain C region X; Ig lambda-2 chain C region

ALTERNATIVE UPACC:
P0DOY2; A0A075B6K9; A0M8Q4; P0CG05; P0CG06; P80423

BACKGROUND:
The Immunoglobulin lambda constant 2 protein, with aliases such as Ig lambda chain C region SH and Ig lambda chain C region X, is integral to the immune system's ability to recognize and neutralize pathogens. It contributes to the antigen-antibody interaction, a cornerstone of adaptive immunity, facilitating the clonal expansion of B lymphocytes into plasma cells that secrete specific antibodies. These antibodies possess unique antigen binding sites, enabling precise targeting and elimination of antigens.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Immunoglobulin lambda constant 2 offers a pathway to innovative therapeutic approaches. Its critical role in antibody-mediated immunity underscores its potential as a target for interventions aimed at enhancing immune response or treating autoimmune diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.